Pharmacopeia, a leader in the discovery and development of novel small molecule therapeutics recently announced its exclusive licensing agreement with Bristol-Myers Squibb Company for worldwide development and commercialization rights to compounds discovered by Bristol-Myers Squibb that possess dual angiotensin (AT1) and endothelin (ETA) receptor antagonist (DARA) activity.
Pharmacopeia’s most advanced internal programs are: dual angiotensin (AT1) and endothelin (ETA) receptor antagonists (DARA) (for cardiovascular disease); JAK3 inhibitors (immunomodulators for multiple potential indications, including transplant rejection, psoriasis and rheumatoid arthritis); CCR1 antagonists (with potential application in the treatment of inflammatory diseases such as rheumatoid arthritis and multiple sclerosis); and adenosine A2a antagonists (with potential application in neurodegenerative diseases, including Parkinson’s and Alzheimer’s).
As stated in the terms of the agreement, Pharmacopeia will provide Bristol-Myers Squibb with a set of compound libraries and further pay Bristol-Myers Squibb milestone payments upon the achievement of clinical and regulatory milestones, and royalties on sales of products, if any, resulting from the program.
Read full press release.
.jpg)
Comment Preview